VORANIGO® is the only FDA-approved treatment designed specifically for people who have IDH-mutant astrocytoma or oligodendroglioma.
If you’re living with IDH-mutant astrocytoma or oligodendroglioma,
YOU’RE LIVING FOR
these
moments
VORANIGO is a once-daily pill
that can help halt progression* and
delay the need for additional treatment.
VORANIGO is a once-daily pill that can
help halt progression* and delay the
need for additional treatment.
*
VORANIGO helped people live longer without their tumor growing.
* VORANIGO helped people live longer without their tumor growing.
Explore VORANIGO
VORANIGO is proven to
Help
HALT
PROGRESSION
VORANIGO helped people live longer without their tumor growing
DELAY
THE NEED FOR
ADDITIONAL TREATMENT
See the results of the VORANIGO clinical trial Explore VORANIGO
VORANIGO
is proven to
Help
HALT
PROGRESSION
VORANIGO helped people live longer without their tumor growing
&
DELAY
THE NEED FOR
ADDITIONAL TREATMENT
See the results of the VORANIGO clinical trial

IS VORANIGO an option for you?

Take this short assessment to learn if VORANIGO is appropriate for you or a loved one and explore resources to help you start the conversation with your healthcare provider.
SEE
Rob’s story
Rob shares his story about living with oligodendroglioma, staying positive, and moving forward with VORANIGO.
Watch now

Share your VORANIGO STORY

How are you moving forward with VORANIGO in your daily life? Sharing your VORANIGO story can have a positive impact on others living with IDH-mutant glioma.
Share your VORANIGO story
Find out
HOW VORANIGO WORKS TO DELAY DISEASE PROGRESSION
Explore
HELPFUL RESOURCES FOR TALKING TO YOUR DOCTOR ABOUT VORANIGO
Your Toolkit
Are you eligible for VORANIGO?
Talk to your doctor about VORANIGO
The VORANIGO
$25 Copay Program
Important Safety Information
What is VORANIGO?
VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, following surgery. Your healthcare provider will perform a test to make sure that VORANIGO is right for you. It is not known if VORANIGO is safe and effective in children under 12 years of age.
What are the possible side effects of VORANIGO?
VORANIGO may cause serious side effects, including:
  • Liver problems. Changes in liver function blood tests may happen during treatment with VORANIGO and can be serious. Your healthcare provider will do blood tests to check your liver function before and during treatment with VORANIGO. Tell your healthcare provider right away if you develop any of the following signs and symptoms of liver problems:
    • yellowing of your skin or the white part of your eyes (jaundice)
    • dark tea-colored urine
    • loss of appetite
    • pain on the upper right side of your stomach area
    • feeling very tired or weak
What is VORANIGO?
VORANIGO (40 mg tablets) is a prescription medicine used to treat adults and children 12 years of age and older with certain types of brain tumors called astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, following surgery. Your healthcare provider will perform a test to make sure that VORANIGO is right for you. It is not known if VORANIGO is safe and effective in children under 12 years of age.
What are the possible side effects of VORANIGO?
VORANIGO may cause serious side effects, including:
The most common side effects of VORANIGO include:
Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with VORANIGO if you have certain side effects.
VORANIGO may affect fertility in females and males, which may affect the ability to have children. Talk to your healthcare provider if this is a concern for you.
These are not all of the possible side effects of VORANIGO.
Before taking VORANIGO, tell your healthcare provider about all of your medical conditions, including if you:
Females who are able to become pregnant:
Males with female partners who are able to become pregnant:
Tell your healthcare provider if you are breastfeeding or plan to breastfeed. It is not known if VORANIGO passes into breast milk. Do not breastfeed during treatment with VORANIGO and for 2 months after the last dose.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VORANIGO may affect the way other medicines work, and other medicines may affect how VORANIGO works.